Amer Karam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amer Karam has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Oliver Dorigo
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford School of Medicine, Stanford Women's Cancer Center and Stanford Cancer Institute, 300 Pasteur Drive, Stanford, CA 94305, USA
7 shared publicationsBeth Y. Karlan
4 shared publications- Malte Renz
Department of Gynecology with Center for Oncological Surgery, Charité – Universitätsmedizin Berlin, Berlin, Germany
4 shared publications Elisabeth Diver
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford School of Medicine, Stanford Women's Cancer Center and Stanford Cancer Institute, 300 Pasteur Drive, Stanford, CA 94305, USA
3 shared publicationsBabak Litkouhi
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford School of Medicine, Stanford Women's Cancer Center and Stanford Cancer Institute, 300 Pasteur Drive, Stanford, CA 94305, USA
2 shared publicationsBrooke Howitt
Department of Pathology, Stanford School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
2 shared publications
Latest Publications
- 18 February 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 206, 93-98
Pre-operative cross-sectional imaging of chest, abdomen, pelvis is not cost-effective for low-grade endometrial cancer
- 18 February 2026
- Published by Elsevier in Gynecologic Oncology
- Vol. 206, 93-98
Pre-operative cross-sectional imaging of chest, abdomen, pelvis is not cost-effective for low-grade endometrial cancer
- Open Access
- 26 June 2025
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 60, 101798
Exceptional response to trastuzumab deruxtecan in recurrent neuroendocrine cervical cancer: A case report
- 26 June 2025
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 60, 101798
Open AccessExceptional response to trastuzumab deruxtecan in recurrent neuroendocrine cervical cancer: A case report
- Open Access
- 7 April 2025
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 59, 101738
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer
- 7 April 2025
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 59, 101738
Open AccessEarly experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer
- Open Access
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S18
32 Trends in ovarian cancer incidence and incidence-based mortality: a 15-year population-based analysis
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S18
Open Access32 Trends in ovarian cancer incidence and incidence-based mortality: a 15-year population-based analysis
- Open Access
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S36
70 Surgical outcomes for robotic-assisted single-site hysterectomy as compared to multi-site hysterectomy: a single institution retrospective study
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S36
Open Access70 Surgical outcomes for robotic-assisted single-site hysterectomy as compared to multi-site hysterectomy: a single institution retrospective study
- Open Access
- 30 July 2022
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 43, 101054
Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer
- 30 July 2022
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 43, 101054
Open AccessTechnetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer
- 15 December 2021
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 34 (1) , 15-19
Role of sentinel lymph node biopsy for gynecologic cancers
Purpose of review: To provide an overview of the current knowledge and recent advances of sentinel lymph node (SLN) assessment in uterine, cervical, vulvar, and ovarian cancers. Recent findings: In endometrial cancer, SLN evaluation has become increasingly utilized as part of the treatment of early-stage disease, with data showing improved detection of pelvic lymph node metastasis. In cervical cancer, SLN biopsy has also gained increasing traction with studies demonstrating the feasibility and accuracy of SLN detection. Evaluation with frozen section, however, remains limited in the detection of metastases. The prognostic significance of positive SLN in vulvar cancer is currently being investigated, with preliminary data showing lower recurrence rates in patients receiving adjuvant radiation. Summary: SLN evaluation remains standard of care to detect lymph node metastasis in early-staged endometrial cancer. In cervical cancer, SLN biopsy has been shown to be reliable, while decreasing morbidity without impacting disease-free survival in select patients. The technique and high sensitivity of SLN biopsy in vulvar cancer has been demonstrated in large prospective trials. There are no randomized controlled trials in ovarian cancer that evaluate the role of SLN biopsy on treatment and outcome; current SLN evaluation remains investigational.
- 15 December 2021
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 34 (1) , 15-19
Role of sentinel lymph node biopsy for gynecologic cancers
Purpose of review: To provide an overview of the current knowledge and recent advances of sentinel lymph node (SLN) assessment in uterine, cervical, vulvar, and ovarian cancers. Recent findings: In endometrial cancer, SLN evaluation has become increasingly utilized as part of the treatment of early-stage disease, with data showing improved detection of pelvic lymph node metastasis. In cervical cancer, SLN biopsy has also gained increasing traction with studies demonstrating the feasibility and accuracy of SLN detection. Evaluation with frozen section, however, remains limited in the detection of metastases. The prognostic significance of positive SLN in vulvar cancer is currently being investigated, with preliminary data showing lower recurrence rates in patients receiving adjuvant radiation. Summary: SLN evaluation remains standard of care to detect lymph node metastasis in early-staged endometrial cancer. In cervical cancer, SLN biopsy has been shown to be reliable, while decreasing morbidity without impacting disease-free survival in select patients. The technique and high sensitivity of SLN biopsy in vulvar cancer has been demonstrated in large prospective trials. There are no randomized controlled trials in ovarian cancer that evaluate the role of SLN biopsy on treatment and outcome; current SLN evaluation remains investigational.
- 1 December 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 163 (3) , 448-452
Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement
- 1 December 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 163 (3) , 448-452
Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement
- Open Access
High-Risk Endometrial Cancer Assessed by Immediate Intraoperative Frozen Sections of Sentinel Lymph Nodes – A Retrospective Study
While sentinel lymph node (SLN) sampling has been established for low-risk endometrial cancer, few data exists on high-risk histologies. This study aims to measure the accuracy of immediate intraoperative SLN biopsy with frozen section in high-risk endometrial cancer. Patients diagnosed with endometrial cancer of high-grade histology (grade 3 endometrioid, clear cell, serous, carcinosarcoma, de- or undifferentiated histology) between 2014 and 2019 at a single institution who underwent SLN mapping, followed by pelvic lymphadenectomy with or without para-aortic lymphadenectomy were included. SLNs were assessed intraoperatively using multiple frozen sections and H&E staining. Lymph node metastases detected by SLN biopsy were compared with complete lymphadenectomy specimens. 35 patients with high-grade endometrial cancer histology underwent SLN mapping followed by lymphadenectomy. In 34 of 35 (97%) of these patients mapping with at least one SLN was successful. Positive SLNs were identified in 7/34 patients (20.6%). There were no patients who had positive lymph nodes on complete lymphadenectomy without a positive SLN, resulting in 100% sensitivity, and 0% false-negative rate. SLN mapping using intraoperative frozen sections in high-risk endometrial cancer demonstrated 100% sensitivity and 0% false-negative rate, provides immediate feedback on successful SLN mapping and valuable intraoperative information on the disease status guiding the intraoperative decision for completion lymphadenectomy. Highlights Intraoperative SLN assessment in high-grade endometrial cancer by frozen section. 100% sensitivity and 0% false-negative rate compared to complete lymphadenectomy. Protocol provides immediate intraoperative feedback on successful SLN mapping. Protocol helps inform surgeon’s decision to proceed with complete lymphadenectomy.
Open AccessHigh-Risk Endometrial Cancer Assessed by Immediate Intraoperative Frozen Sections of Sentinel Lymph Nodes – A Retrospective Study
While sentinel lymph node (SLN) sampling has been established for low-risk endometrial cancer, few data exists on high-risk histologies. This study aims to measure the accuracy of immediate intraoperative SLN biopsy with frozen section in high-risk endometrial cancer. Patients diagnosed with endometrial cancer of high-grade histology (grade 3 endometrioid, clear cell, serous, carcinosarcoma, de- or undifferentiated histology) between 2014 and 2019 at a single institution who underwent SLN mapping, followed by pelvic lymphadenectomy with or without para-aortic lymphadenectomy were included. SLNs were assessed intraoperatively using multiple frozen sections and H&E staining. Lymph node metastases detected by SLN biopsy were compared with complete lymphadenectomy specimens. 35 patients with high-grade endometrial cancer histology underwent SLN mapping followed by lymphadenectomy. In 34 of 35 (97%) of these patients mapping with at least one SLN was successful. Positive SLNs were identified in 7/34 patients (20.6%). There were no patients who had positive lymph nodes on complete lymphadenectomy without a positive SLN, resulting in 100% sensitivity, and 0% false-negative rate. SLN mapping using intraoperative frozen sections in high-risk endometrial cancer demonstrated 100% sensitivity and 0% false-negative rate, provides immediate feedback on successful SLN mapping and valuable intraoperative information on the disease status guiding the intraoperative decision for completion lymphadenectomy. Highlights Intraoperative SLN assessment in high-grade endometrial cancer by frozen section. 100% sensitivity and 0% false-negative rate compared to complete lymphadenectomy. Protocol provides immediate intraoperative feedback on successful SLN mapping. Protocol helps inform surgeon’s decision to proceed with complete lymphadenectomy.
- 1 August 2020
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 30 (8) , 1118-1123
Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review
Objective Vulvar cancers account for 5% of all gynecologic malignancies; only 1%–3% of those vulvar cancers are primary vulvar sarcomas. Given the rarity of vulvar sarcomas, outcome data specific to histopathologic subtypes are sparse. The aim of this study was to identify clinical and pathologic factors of primary vulvar sarcomas that are associated with survival and may inform treatment decisions. Methods The Surveillance, Epidemiology, and End Results (SEER) database was searched for women diagnosed with vulvar sarcoma between 1973 and 2018. We identified 315 patients and reviewed their demographic, clinicopathologic, surgical, and survival information. Statistical analyses included χ2 and t-tests, Kaplan–Meier survival, and Cox regression analyses. Results The most common histopathologies of vulvar sarcomas were dermatofibrosarcomas (85/315, 27%) and leiomyosarcomas (72/315, 22.9%). Rhabdomyosarcomas (18/315, 5.7%), liposarcomas (16/315, 5.1%), and malignant fibrous histiocytomas (16/315, 5.1%) were less frequent. The majority of patients underwent surgery (292/315, 92.7%), which included lymph node dissections in 21.6% (63/292). Survival and lymph node involvement varied significantly with histologic subtype. The 5-year disease-specific survival for dermatofibrosarcomas, liposarcomas, and fibrosarcomas was 100% and only 60.3% and 62.5% for malignant fibrous histiocytomas and rhabdomyosarcomas, respectively. None of the patients with (dermato)fibrosarcomas, liposarcomas, or leiomyosarcomas had positive lymph nodes, in contrast to rhabdomyosarcomas and malignant fibrous histiocytomas with 77.8% and 40% positive lymph nodes, respectively. The 5-year disease-specific survival for women with positive lymph nodes was 0%. Conclusions Vulvar sarcomas are heterogeneous with survival highly dependent on the histopathologic subtype. While surgical excision is the mainstay of treatment for all vulvar sarcomas, staging lymphadenectomy should be deferred for (dermato)fibrosarcomas, liposarcomas, and leiomyosarcomas as there were no cases of lymph nodes metastases.
- 1 August 2020
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 30 (8) , 1118-1123
Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review
Objective Vulvar cancers account for 5% of all gynecologic malignancies; only 1%–3% of those vulvar cancers are primary vulvar sarcomas. Given the rarity of vulvar sarcomas, outcome data specific to histopathologic subtypes are sparse. The aim of this study was to identify clinical and pathologic factors of primary vulvar sarcomas that are associated with survival and may inform treatment decisions. Methods The Surveillance, Epidemiology, and End Results (SEER) database was searched for women diagnosed with vulvar sarcoma between 1973 and 2018. We identified 315 patients and reviewed their demographic, clinicopathologic, surgical, and survival information. Statistical analyses included χ2 and t-tests, Kaplan–Meier survival, and Cox regression analyses. Results The most common histopathologies of vulvar sarcomas were dermatofibrosarcomas (85/315, 27%) and leiomyosarcomas (72/315, 22.9%). Rhabdomyosarcomas (18/315, 5.7%), liposarcomas (16/315, 5.1%), and malignant fibrous histiocytomas (16/315, 5.1%) were less frequent. The majority of patients underwent surgery (292/315, 92.7%), which included lymph node dissections in 21.6% (63/292). Survival and lymph node involvement varied significantly with histologic subtype. The 5-year disease-specific survival for dermatofibrosarcomas, liposarcomas, and fibrosarcomas was 100% and only 60.3% and 62.5% for malignant fibrous histiocytomas and rhabdomyosarcomas, respectively. None of the patients with (dermato)fibrosarcomas, liposarcomas, or leiomyosarcomas had positive lymph nodes, in contrast to rhabdomyosarcomas and malignant fibrous histiocytomas with 77.8% and 40% positive lymph nodes, respectively. The 5-year disease-specific survival for women with positive lymph nodes was 0%. Conclusions Vulvar sarcomas are heterogeneous with survival highly dependent on the histopathologic subtype. While surgical excision is the mainstay of treatment for all vulvar sarcomas, staging lymphadenectomy should be deferred for (dermato)fibrosarcomas, liposarcomas, and leiomyosarcomas as there were no cases of lymph nodes metastases.